Psoriatic arthritis (PsA) and axial Spondyloarthritis (axSpA) share some common therapeutic options, namely TNF-inhibitors, anti-IL-17 and JAK-inhibitors. The gene discussed is TNF; the disease is psoriatic arthritis.